目的 探討平消膠囊聯(lián)合SOX方案治療晚期胃癌的療效。方法 選取2018年6月—2020年2月北京航天總醫(yī)院收治的102例晚期胃癌患者作為研究對(duì)象，將所有患者按照治療方法分為對(duì)照組與觀察組，每組各51例。對(duì)照組患者給予SOX方案化療，即口服替吉奧膠囊，初始劑量根據(jù)體表面積確定：體表面積<1.25 m²者40 mg/次，1.25～1.5 m²者50 mg/次，>1.5 m²者60 mg/次，均為2次/d，分別于早晚飯后服用，連續(xù)服用2周后停藥1周；第1天奧沙利鉑注射液，130 mg/m²，靜脈滴注3 h。觀察組在對(duì)照組治療的基礎(chǔ)上口服平消膠囊，5粒/次，3次/d，于化療1周后開始服用。治療4周后觀察各指標(biāo)變化情況。觀察兩組患者的臨床療效，同時(shí)比較兩組的血清糖類抗原242（CA242）、糖類抗原125（CA125）、糖類抗原199（CA199）和癌胚抗原（CEA）水平，外周血轉(zhuǎn)化生長(zhǎng)因子-α（TGF-α）和腺苷酸活化蛋白激酶5（ARK5）水平；CD4+T淋巴細(xì)胞亞型Th17細(xì)胞、CD4⁺CD25⁺調(diào)節(jié)性T淋巴細(xì)胞（Treg）及Th17/Treg比值；觀察并記錄兩組無進(jìn)展生存期（PFS）和總生存期（OS）。結(jié)果 治療后，觀察組疾病控制率為73.47%，顯著高于對(duì)照組的54.00%，兩組比較差異有統(tǒng)計(jì)學(xué)意義（P<0.05）。治療后，兩組CA242、CA125、CA199、CEA水平顯著低于治療前（P<0.05），觀察組CA242、CA125、CA199、CEA水平顯著低于對(duì)照組（P<0.05）。治療后，兩組Th17、Treg、Th17/Treg均值低于治療前（P<0.05）；治療后，觀察組Th17、Treg、Th17/Treg值顯著低于對(duì)照組（P<0.05）。治療后，觀察組患者PFS和OS為均長(zhǎng)于對(duì)照組，差異有統(tǒng)計(jì)學(xué)意義（P<0.05）。治療后，兩組外周血TGF-α、ARK5水平均顯著低于治療前（P<0.05）；且觀察組治療后外周血TGF-α、ARK5水平顯著低于對(duì)照組（P<0.05）。結(jié)論 平消膠囊聯(lián)合SOX方案治療晚期胃癌療效顯著，可有效降低腫瘤標(biāo)志物水平，抑制腫瘤生長(zhǎng)，改善患者的免疫功能，延長(zhǎng)生存期，改善預(yù)后，降低TGF-α、ARK5水平，抑制腫瘤轉(zhuǎn)移，促進(jìn)腫瘤細(xì)胞凋亡，同時(shí)還能降低毒副反應(yīng)的發(fā)生率，安全性較高。

Objective To investigate the effect of Pingxiao Capsules combined with SOX regimen in treatment of advanced gastric cancer. Methods A total of 102 patients with advanced gastric cancer admitted to Beijing Aerospace General Hospital from June 2018 to February 2020 were selected as the research subjects. All the patients were divided into control group and observation group according to treatment methods, with 51 patients in each group. Patients in the control group were received SOX regimen chemotherapy, patients were po administered with Tegafur, Gimeracil and Oteracil Potassium Capsules, and the initial dose was determined according to the body surface area: 40 mg/time in subjects with body surface area < 1.25 m², 50 mg/time in subjects with body surface area 1.25 — 1.5 m², and 60 mg/time in subjects with > 1.5 m², twice daily, were given at night and after meals, respectively. After 2 weeks of continuous administration, the drug was stopped for 1 week. On day 1, Oxaliplatin Injection was given 130 mg/m² intravenously for 3 h. Patients in the observation group were po administered with Pingxiao Capsules on the basis of control group, 5 grains/time, three times daily, and began to take them 1 week after chemotherapy. The changes of all indexes were observed after 4 weeks of treatment. Clinical efficacy of two groups was observed. The serum levels of CA242, CA125, CA199, CEA, and TGF-α, ARK5 levels in the peripheral blood, the ratio of Th17, Treg, Th17/Treg were compared between two group. And PFS and were observed and recorded in both groups. Results After treatment, the disease control rate of the observation group was 73.47%, significantly higher than 54.00% of the control group, and the difference between the two groups was statistically significant (P < 0.05). After treatment, the levels of CA242, CA125, CA199, and CEA in two groups were significantly lower than before treatment (P < 0.05), and the levels of CA242, CA125, CA199, and CEA in observation group were significantly lower than those in control group (P < 0.05). After treatment, the mean values of Th17, Treg, and Th17/Treg in two groups were lower than those before treatment (P < 0.05). After treatment, the values of Th17, Treg, and Th17/Treg in observation group were significantly lower than those in control group (P < 0.05). After treatment, PFS and OS of observation group were longer than control group, the difference was statistically significant (P < 0.05). After treatment, the levels of TGF-α and ARK5 in peripheral blood of two groups were significantly lower than before treatment (P < 0.05). The levels of TGF-α and ARK5 in peripheral blood of observation group were significantly lower than those of control group after treatment (P < 0.05). Conclusion Pingxiao Capsules combined with SOX regimen for advanced gastric cancer curative effect significantly, can effectively reduce the levels of tumor markers, inhibit tumor growth, improve the patient's immune function, prolong the survival period, improve prognosis, lower levels of TGF-α, ARK5, inhibiting tumor metastasis, promote tumor cell apoptosis, at the same time also can reduce the incidence rate of adverse reaction, with high security.